Insight Molecular Diagnostics Inc. (IMDX) — Strategic Asset Allocation Index
Insight Molecular Diagnostics Inc. (IMDX) has a Strategic Asset Allocation Index of 0.0% as of December 2021. Strategic assets (PP&E of $- plus long-term investments of $0.00) total $0.00, measured against net assets of $65.22 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check IMDX cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
SAAI
Strategic Assets
PP&E
Net Assets
Insight Molecular Diagnostics Inc. Strategic Asset Allocation Index (2021–2021)
This chart shows how Insight Molecular Diagnostics Inc.'s Strategic Asset Allocation Index has evolved across 1 annual periods from 2021 to 2021. As of December 2021, the index stands at 0.0%, representing strategic assets of $0.00 against net assets of $65.22 Million USD. See financial flexibility index of Insight Molecular Diagnostics Inc. to measure the company's free cash flow as a share of total liabilities.
Annual Strategic Asset Allocation Index for Insight Molecular Diagnostics Inc. (2021–2021)
The table below presents the year-by-year Strategic Asset Allocation Index for Insight Molecular Diagnostics Inc. from 2021 to 2021, covering 1 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see how much is Insight Molecular Diagnostics Inc. worth.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 0.0% | $0.00 | $- | $0.00 | $65.22 Million | — |